Compare Stocks: GNPX, ERNA, XCUR, and MTVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERNA Ernexa Therapeutics	$4.93 -2.0%	$5.22	$3.18 ▼ $71.50	$8.22M	2.57	42,350 shs	81,849 shs
GNPX Genprex	$4.00 -0.5%	$8.21	$3.83 ▼ $1,210.00	$3.30M	-0.88	469,063 shs	71,682 shs
MTVA MetaVia	$1.64 +7.2%	$1.55	$0.97 ▼ $19.03	$7.90M	0.95	74,314 shs	246,208 shs
XCUR Exicure	$1.19 +3.5%	$1.76	$1.05 ▼ $9.48	$7.53M	3.65	46,016 shs	19,163 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERNA Ernexa Therapeutics	-1.99%	+16.00%	+25.45%	-55.75%	-86.24%
GNPX Genprex	-0.50%	+1.27%	-48.78%	-76.58%	-97.80%
MTVA MetaVia	+7.19%	+10.07%	+10.81%	-50.90%	-77.06%
XCUR Exicure	+3.48%	-16.78%	-32.39%	-57.35%	-79.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERNA Ernexa Therapeutics	$4.93 -2.0%	$5.22	$3.18 ▼ $71.50	$8.22M	2.57	42,350 shs	81,849 shs
GNPX Genprex	$4.00 -0.5%	$8.21	$3.83 ▼ $1,210.00	$3.30M	-0.88	469,063 shs	71,682 shs
MTVA MetaVia	$1.64 +7.2%	$1.55	$0.97 ▼ $19.03	$7.90M	0.95	74,314 shs	246,208 shs
XCUR Exicure	$1.19 +3.5%	$1.76	$1.05 ▼ $9.48	$7.53M	3.65	46,016 shs	19,163 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERNA Ernexa Therapeutics	-1.99%	+16.00%	+25.45%	-55.75%	-86.24%
GNPX Genprex	-0.50%	+1.27%	-48.78%	-76.58%	-97.80%
MTVA MetaVia	+7.19%	+10.07%	+10.81%	-50.90%	-77.06%
XCUR Exicure	+3.48%	-16.78%	-32.39%	-57.35%	-79.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERNA Ernexa Therapeutics	2.00	Hold	$30.00	508.52% Upside
GNPX Genprex	1.00	Sell	N/A	N/A
MTVA MetaVia	2.00	Hold	$20.00	1,119.51% Upside
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GNPX, ERNA, XCUR, and MTVA Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/21/2026	MTVA MetaVia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	ERNA Ernexa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/11/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/28/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERNA Ernexa Therapeutics	$580K	13.86	N/A	N/A	$1.96 per share	2.52
GNPX Genprex	N/A	N/A	N/A	N/A	$18.05 per share	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	$1.32 per share	N/A
XCUR Exicure	$500K	15.59	N/A	N/A	$0.15 per share	7.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERNA Ernexa Therapeutics	-$14.08M	-$14.35	N/A	N/A	N/A	N/A	-305.93%	-169.86%	11/6/2026 (Estimated)
GNPX Genprex	-$16.23M	-$133.36	N/A	N/A	N/A	N/A	-163.12%	-128.98%	9/2/2026 (Estimated)
MTVA MetaVia	-$12.97M	-$3.23	N/A	N/A	N/A	N/A	-209.67%	-107.91%	11/5/2026 (Estimated)
XCUR Exicure	-$4.95M	-$1.32	N/A	N/A	N/A	N/A	-237.91%	-61.98%	11/12/2026 (Estimated)

Latest GNPX, ERNA, XCUR, and MTVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GNPX Genprex	N/A	-$9.40	N/A	-$9.40	N/A	N/A
8/14/2026	Q2 2026	XCUR Exicure	-$18.60	-$0.18	+$18.42	-$0.18	$1.64 million	N/A
8/6/2026	Q2 2026	ERNA Ernexa Therapeutics	-$3.30	-$3.40	-$0.10	-$3.40	N/A	N/A
8/6/2026	Q2 2026	MTVA MetaVia	-$0.82	-$0.90	-$0.08	-$0.90	N/A	N/A
5/29/2026	Q1 2026	XCUR Exicure	-$18.60	-$0.29	+$18.31	-$0.29	$1.64 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERNA Ernexa Therapeutics	N/A	2.01	2.01
GNPX Genprex	N/A	6.76	6.76
MTVA MetaVia	N/A	2.06	2.06
XCUR Exicure	N/A	0.56	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERNA Ernexa Therapeutics	70.55%
GNPX Genprex	14.05%
MTVA MetaVia	1.37%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
ERNA Ernexa Therapeutics	0.53%
GNPX Genprex	0.25%
MTVA MetaVia	0.60%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERNA Ernexa Therapeutics	10	1.63 million	1.62 million	No Data
GNPX Genprex	20	820,000	818,000	No Data
MTVA MetaVia	8	5.16 million	5.13 million	N/A
XCUR Exicure	50	6.55 million	3.09 million	Not Optionable

GNPX, ERNA, XCUR, and MTVA Headlines

Recent News About These Companies

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics

August 3, 2026 | quiverquant.comQ

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

August 3, 2026 | globenewswire.com

Exicure Inc (NASDAQ: XCUR) - Share Price and Research

July 15, 2026 | intelligentinvestor.com.auI

Exicure Reaches Preliminary Settlement in Derivative Lawsuits

July 9, 2026 | theglobeandmail.com

Exicure Announces Board and Committee Changes

June 30, 2026 | globenewswire.com

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11, 2026 | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10, 2026 | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10, 2026 | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

April 2, 2026 | globenewswire.com

Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing

March 25, 2026 | quiverquant.comQ

Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing

March 25, 2026 | quiverquant.comQ

Exicure, Inc. Reports Full Year 2025 Financial Results

March 25, 2026 | globenewswire.com

Exicure, Inc. Reports Full Year 2025 Financial Results

March 25, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GNPX, ERNA, XCUR, and MTVA Company Descriptions

Ernexa Therapeutics NASDAQ:ERNA

$4.93 -0.10 (-1.99%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$5.12 +0.19 (+3.75%)

As of 08/25/2026 05:33 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Genprex NASDAQ:GNPX

$4.00 -0.02 (-0.50%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$3.97 -0.03 (-0.75%)

As of 08/25/2026 05:31 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

MetaVia NASDAQ:MTVA

$1.64 +0.11 (+7.19%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.64 0.00 (-0.30%)

As of 08/25/2026 05:43 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Exicure NASDAQ:XCUR

$1.19 +0.04 (+3.48%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.20 +0.02 (+1.26%)

As of 08/25/2026 05:38 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, ERNA, XCUR, and MTVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, ERNA, XCUR, and MTVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, ERNA, XCUR, and MTVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNPX, ERNA, XCUR, and MTVA Company Descriptions

Ernexa Therapeutics NASDAQ:ERNA

Genprex NASDAQ:GNPX

MetaVia NASDAQ:MTVA

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, ERNA, XCUR, and MTVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, ERNA, XCUR, and MTVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, ERNA, XCUR, and MTVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNPX, ERNA, XCUR, and MTVA Company Descriptions

Ernexa Therapeutics NASDAQ:ERNA

Genprex NASDAQ:GNPX

MetaVia NASDAQ:MTVA

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools